"I had the chance to work with Scott a few years ago in a pediatric IBD clinical study that happened to be in a terminal stage. It is no secret how difficult it is to recruit pediatric studies. When Scott joined the team it was a turning point. Scott's clinical knowledge and excellent management of the clinical team was determinant to complete the study and obtained the pediatric indication of Lialda by the FDA."
"I had the opportunity to work with Scott while he served as the Clinical Program Director on a very complex clinical program that was a part of my immunology portfolio. The program Scott was leading was for a rare indication. In order to effectively conduct the clinical trial, a unique partnership was formed between our organization, an expert Consortium, and a CRO. Scott was instrumental in the formation and the ongoing management of this complex partnership across the three organizations. He demonstrated great expertise in the development of the budget and contracts, strategically managed communications and expectations of all parties, and effectively mentored junior employees on his program. I truly enjoyed working with Scott and would not hesitate to work with him in the future."
"Scott and I worked together on an incredibly complex early phase trial while I was at Genentech leading a group of medical directors and clinical scientists. In all the years I have worked in clinical trials, this study was the single most challenging one, as the different parties (the industry Sponsor, the CRO a global academic consortium, and multiple academic sites/investigators) all came to the collaboration with very different cultures, expectations, goals, experience, and perspectives.
Scott was the Clinical Program Director on this program (and others as well at the same time!) and masterfully handled all of these immense challenges: he patiently and persistently made progress. And always with a big smile and a personal touch! He helped organize numerous meetings including a highly impactful and unusually complex Investigator Meeting (one of the best sites had ever joined!), helped move contracts forward, found creative solutions to complex problems (very hard to do within a large company where this collaborative model was novel and unique), maintained excellent relationships with all stakeholders (not an easy task!), and was a true driving force for this project.
Through all of this, he kept the patients that we serve first and foremost, and used this guiding principle to help make progress—realizing that everyone, regardless of their institution and perspective—can appreciate that rare disease drug development is ultimately for the benefit and health of our patients and loved ones.
The ultimate goal on this project was to save lives and Scott never lost sight of that! I am really looking forward to my next opportunity to work with Scott, and I highly recommend him!"